What is Plexision?
Plexision operates at the intersection of biotechnology and personalized medicine, specializing in the creation of cellular biomarkers. These biomarkers are crucial for advancing diagnostics and drug development, with a particular emphasis on solid organ transplantation and immunological disorders. The company offers a suite of FDA-approved blood tests designed to predict transplant rejection and evaluate cellular immunity against viral infections, including COVID-19. Beyond its diagnostic tools, Plexision also undertakes custom research and development initiatives to embed biomarker targets across all stages of pharmaceutical development. Its operations are anchored in a CLIA-certified, state-of-the-art laboratory situated in Pittsburgh, Pennsylvania.
How much funding has Plexision raised?
Plexision has raised a total of $406K across 2 funding rounds:
Debt
$41K
Other Financing Round
$365K
Debt (2021): $41K with participation from PPP
Other Financing Round (2025): $365K led by Richard King Mellon Foundation
Key Investors in Plexision
Richard King Mellon Foundation
The Richard King Mellon Foundation is a prominent philanthropic organization supporting innovation in Southwestern Pennsylvania and environmental conservation nationwide. It provides funding across six key programs, including Health & Well-Being and Social-Impact Investments, indicating a strategic interest in advancements that improve health outcomes and societal well-being.
PPP
Public-Private Partnership
What's next for Plexision?
With a substantial infusion of capital and a recent strategic investment, Plexision is well-positioned for its next phase of growth. The company's focus on personalized diagnostics and drug development, particularly in the critical areas of transplantation and immunology, aligns with major trends in healthcare. The recent financing, described as a major strategic investment, suggests a strong validation of Plexision's technology and market strategy by its backers. This capital infusion will likely accelerate product development, expand clinical trial capabilities, and potentially broaden market penetration for its FDA-approved diagnostic tests. The company's trajectory indicates a move towards scaling its operations and solidifying its role as a key player in precision medicine.
See full Plexision company page
